AMG 193 Safe, Effective in Multiple Cancer Types

The tumor-selective PRMT5 inhibitor AMG 193 showed promising safety and antitumor activity in non–small cell lung, pancreatic, and biliary duct cancer. Grade 3 or higher adverse events were low, and partial responses were seen across cancer types, supporting further trials for this and other MTA-cooperative PRMT5 inhibitors.